Form 4: Arcutis CEO Sells Shares for Tax Obligations

Arcutis Biotherapeutics CEO Todd Watanabe sold 11,547 shares of common stock on November 3, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• The transactions occurred on November 3, 2025.
• A total of 11,478 shares were sold at a weighted average price of $24.7122 per share, with prices ranging from $24.31 to $25.31.
• An additional 69 shares were sold at a weighted average price of $25.3991 per share, with prices ranging from $25.3361 to $25.40.
• The sales were made to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• Following these transactions, Todd Watanabe directly beneficially owns 794,893 shares of common stock.
• Indirect beneficial ownership includes 25,410 shares held by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations upon RSU vesting, which is a neutral event and does not reflect a change in management's confidence or company performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This transaction represents a routine insider sale for tax purposes, a common occurrence across all industries when executives receive equity compensation that vests. It does not reflect specific industry trends or company-specific operational performance.

Related Party Transactions

• Securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee.
• Securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee.
• Securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer.
• Securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related sale and does not signal a change in company fundamentals or management's long-term view.
• Employees: No direct impact indicated by this filing.
• Customers: No direct impact indicated by this filing.
• Suppliers: No direct impact indicated by this filing.
• Creditors: No direct impact indicated by this filing.

Key Dates

Recommendation

The reported transaction is a routine sale of shares by the President and CEO to cover tax withholding obligations associated with the vesting of Restricted Stock Units. This is a common and expected practice for executives and does not indicate a change in the company's fundamentals or management's long-term outlook. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, Insider Trading, Form 4, Stock Sale, RSU, Tax Withholding